<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Neonatal lupus: Epidemiology, pathogenesis, clinical manifestations, and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Neonatal lupus: Epidemiology, pathogenesis, clinical manifestations, and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Neonatal lupus: Epidemiology, pathogenesis, clinical manifestations, and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jill P Buyon, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marisa Klein-Gitelman, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John K Triedman, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph A Garcia-Prats, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Siobhan M Case, MD, MHS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 09, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neonatal lupus (NL) is an autoimmune disease in which passive transfer of autoantibodies from the mother to the fetus results in fetal and neonatal disease. The major manifestations are cardiac and cutaneous findings. The most serious complication of NL is complete heart block (approximately 20 percent have an associated cardiomyopathy at the initial diagnosis or develop it later [
         <a href="#rid1">
          1,2
         </a>
         ]). In this topic review, the cardiac manifestations of NL are referred to as cardiac-NL and can include any degree of block (referred to as congenital heart block [CHB]) that may or may not be accompanied by extranodal disease such as valvular abnormalities, endocardial fibroelastosis, and/or dilated cardiomyopathy. Occasionally, those manifestations may occur in the absence of heart block.
        </p>
        <p>
         This topic reviews the epidemiology, pathogenesis, clinical manifestations, and diagnosis of NL. The management and outcomes of NL are discussed in greater detail separately. Pregnancy in individuals with systemic lupus erythematosus (SLE) and diagnosis and management of fetal arrhythmias are also reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/113264.html" rel="external">
          "Neonatal lupus: Management and outcomes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4679.html" rel="external">
          "Pregnancy in women with systemic lupus erythematosus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6765.html" rel="external">
          "Fetal arrhythmias"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H623514712">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The cardiac manifestations of NL (cardiac-NL), which most commonly involve injury to the conduction system (congenital heart block [CHB]), with complete atrioventricular (AV) block being the most characteristic, occur in approximately 2 percent of offspring of females who have antibodies to Ro/SSA (Sjögren's disease type A antigen) and/or La/SSB (Sjögren's disease type B antigen; albeit anti-La/SSB in isolation is very rare) [
         <a href="#rid3">
          3-8
         </a>
         ]. NL is responsible for 80 to 95 percent of all cases of congenital complete heart block in the absence of structural defects diagnosed in utero or in the neonatal period [
         <a href="#rid9">
          9,10
         </a>
         ]. NL is almost never the cause of heart block occurring after the neonatal period or even after 26 gestational weeks (1 in 20 mothers of children diagnosed after birth had anti-Ro antibodies) [
         <a href="#rid10">
          10
         </a>
         ]. The risk of developing cutaneous manifestations of NL is 4 to 16 percent in offspring of anti-Ro/SSA- and anti-La/SSB-positive mothers [
         <a href="#rid5">
          5,7
         </a>
         ] but is also sometimes associated with antibodies to ribonucleoprotein (RNP) [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         NL is associated with these specific autoantibodies (Ro/SSA, La/SSB) independent of maternal disease. While some mothers may have systemic lupus erythematosus (SLE) and/or Sjögren's disease, in many other cases, the mother is totally asymptomatic and becomes aware of these antibody reactivities solely based upon the finding of a bradyarrhythmia in the fetus or a skin rash in the neonate [
         <a href="#rid12">
          12
         </a>
         ]. Approximately one-half of mothers with these autoantibodies who do not have other evidence of autoimmune disease at the time of the baby's birth later develop symptoms consistent with an autoimmune disease such as dry eyes or dry mouth, arthritis, Raynaud, rashes, or sufficient criteria to be classified with a known autoimmune disease (more commonly Sjögren's disease than SLE) [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="local">
          'Pathogenesis'
         </a>
         below.)
        </p>
        <p>
         The prevalence of anti-Ro/SSA antibodies was initially reported as 0.2 to 0.72 percent in female blood donors [
         <a href="#rid13">
          13
         </a>
         ] and, more recently, as 0.86 percent in healthy females in the general population (this may be an underestimation since a less reliable test for anti-Ro/SSA was used for initial screening) [
         <a href="#rid14">
          14
         </a>
         ]. For patients with SLE, the estimated prevalence of this antibody is 40 percent [
         <a href="#rid15">
          15
         </a>
         ] and, in those with Sjögren's disease, between 60 to 100 percent [
         <a href="#rid15">
          15
         </a>
         ]. The population prevalence of CHB in Finland was reported as 1 in 17,000 live births [
         <a href="#rid16">
          16
         </a>
         ], with the highest annual estimate at 1:6500. However, this may be an underestimation since only children with pacemakers were included and fetal deaths were not captured. If the true prevalence of anti-Ro/SSA approaches 0.9 percent [
         <a href="#rid14">
          14
         </a>
         ] and CHB occurs in 2 percent and recurs in 18 percent [
         <a href="#rid4">
          4,17
         </a>
         ], this could yield approximately 600 to 700 cases per year in the United States based upon the 2012 National Vital Statistics System data of 3,952,841 births. These results are consistent with a crude estimate based upon the 0.5 percent prevalence of anti-Ro/SSA antibodies in asymptomatic pregnant individuals and the rate of CHB of 1 in 15,000 to 1 in 22,000 live births [
         <a href="#rid18">
          18,19
         </a>
         ].
        </p>
        <p>
         The risk of recurrence of CHB is approximately 18 percent [
         <a href="#rid17">
          17
         </a>
         ], and the risk of recurrence of rash is approximately 30 percent [
         <a href="#rid20">
          20
         </a>
         ]. Crossover, with one pregnancy complicated by rash and a subsequent one by heart block, occurs in approximately 13 to 18 percent [
         <a href="#rid20">
          20
         </a>
         ]. However, recurrence rates of CHB do vary since some studies include first-degree block and even isolated endocardial fibroelastosis. In addition, one study suggested that recurrence rates were even higher in pregnancies not exposed to
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         NL is presumed to result from the transplacental passage of maternal anti-Ro/SSA (Sjögren's disease type A antigen) and/or anti-La/SSB (Sjögren's disease type B antigen) antibodies that affect neonatal organs, particularly the heart and skin. The pathogenesis almost assuredly requires more than the presence of these antibodies in the fetal circulation (eg, fetal genetic factors and environmental stressors) [
         <a href="#rid9">
          9,18
         </a>
         ] since even females with extremely high titers, which do increase risk, can have normal pregnancies [
         <a href="#rid22">
          22,23
         </a>
         ]. In addition, discordance of disease in monozygotic twins has been reported. (See
         <a class="medical medical_review" href="/z/d/html/1818.html" rel="external">
          "The anti-Ro/SSA and anti-La/SSB antigen-antibody systems"
         </a>
         .)
        </p>
        <p>
         Although the precise mechanism of injury is not fully elucidated, it is proposed that heart block results from binding of anti-Ro/SSA and/or anti-La/SSB antibodies to fetal cardiac cells that have undergone physiologic apoptosis during remodeling, leading to autoimmune injury and secondary fibrosis of the atrioventricular (AV) node and its surrounding tissue [
         <a href="#rid24">
          24-27
         </a>
         ]. Autoantibodies may also act by inhibiting calcium currents mediated by cardiac L and T type calcium channels [
         <a href="#rid28">
          28-32
         </a>
         ]. L type channels are crucial to action potential propagation and conduction in the AV and sinoatrial (SA) nodes, while the functional role of the T type channel in the AV node is not completely understood. Some studies have suggested a role for type I interferon (IFN) in the pathogenesis based upon transcriptomic evaluation of cells isolated from fetal hearts with CHB [
         <a href="#rid33">
          33,34
         </a>
         ]. In addition, neonates exposed to maternal anti-Ro/La antibodies have higher frequencies of natural killer (NK) cells and increased type I and II IFN gene signatures compared with nonantibody-exposed neonates. These findings were observed in neonates without any cardiac abnormalities, suggesting that these changes, while potentially contributory to the risk of congenital heart block (CHB), are themselves insufficient to promote clinical injury [
         <a href="#rid35">
          35
         </a>
         ]. Other data suggest that fibroblast heterogeneity (S100A4+ expressing and canonical myofibroblasts) induced by anti-Ro/SSA activated macrophage secretion of type I IFN contributes to tissue injury [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Autoantibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several studies have established the association between anti-Ro/SSA and anti-La/SSB antibodies and NL by prospectively monitoring offspring of females with these reactivities [
         <a href="#rid4">
          4-7
         </a>
         ]. Although fetal disease is often referred to as a pathologic readout of passively acquired autoimmune disease, many females with these antibodies are themselves clinically asymptomatic and only identified to have serologic abnormalities when gestational surveillance reveals fetal bradycardia or even after giving birth when the neonate is noted to have bradycardia. This important point may be underappreciated since the term "neonatal lupus" has been applied to the cardiac and skin disease in the offspring, yet the mother may or may not have systemic lupus erythematosus (SLE) and the child does not have SLE. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
         It has been stated that the incidence of CHB is more common in offspring of females with high titers of anti-Ro/SSA and anti-La/SSB compared with mothers with low titers [
         <a href="#rid23">
          23,37-41
         </a>
         ], and very low titers probably confer no risk at all [
         <a href="#rid42">
          42
         </a>
         ]. One study suggested increased risk in those with the highest titers of anti-Ro/SSA60 and supported that enhancing the assay measuring range allows improved specificity of identifying pregnancies at risk of cardiac-NL [
         <a href="#rid23">
          23
         </a>
         ]. However, the difficulty in making such a statement relates to the definition of high titer. The immunoassay used by many commercial laboratories defines values as positive if &gt;1 enzyme-linked immunosorbent assay (ELISA) unit, with a reported upper measurement limit of 8 ELISA units. Even titers &gt;8 may not reach a threshold for the development of NL manifestations. Whether mothers with titers &lt;8 should undergo less frequent surveillance is under debate.
        </p>
        <p>
         Even if "high titers" are established, antibodies alone are not sufficient to result in CHB. The risk of CHB was slightly higher in one study if a mother had antibodies to both Ro/SSA and La/SSB [
         <a href="#rid39">
          39
         </a>
         ] but was independent of anti-La/SSB titers in another [
         <a href="#rid40">
          40
         </a>
         ]. The risk of cutaneous NL was higher in neonates of mothers with both anti-Ro/SSA and anti-La/SSB autoantibodies in one study [
         <a href="#rid5">
          5
         </a>
         ]. In another study, infants exposed to high titers of anti-La/SSB were more likely to have noncardiac manifestations of NL [
         <a href="#rid40">
          40
         </a>
         ]. In addition, one study reported a lower risk of NL in offspring of females with anti-idiotype antibodies to La/SSB [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         In addition to the traditional Ro antigen of 60 kD, another antigen of 52 kD has been identified. Whether this second antigen is really "Ro" remains controversial since Ro52 does not contain a ribonucleic acid (RNA) binding domain. While several studies have attempted to identify specific epitopes within the Ro/SSA and La/SSB antigens that associate with cardiac-NL, most of these studies report epitopes common to the anti-Ro/SSA/La/SSB response regardless of fetal outcome. Moreover, different antibody subsets are identified depending upon the immunoassay used for detection. For example, the sensitivity of peptide or recombinant protein ELISAs for anti-Ro60 antibodies is low and may result in false negatives [
         <a href="#rid39">
          39,44,45
         </a>
         ]. Newer assays that use native antigen for SSA/Ro60 are more sensitive. (See
         <a class="medical medical_review" href="/z/d/html/1818.html" rel="external">
          "The anti-Ro/SSA and anti-La/SSB antigen-antibody systems"
         </a>
         .)
        </p>
        <p>
         The antibody response against the p200 epitope, spanning Ro52 amino acids (aa) 200 to 239, is a candidate biomarker of increased maternal risk for the development of cardiac-NL in an offspring [
         <a href="#rid46">
          46,47
         </a>
         ]. Although several groups have confirmed the high prevalence of the p200 response in females giving birth to a child with cardiac-NL, there have been inconsistencies regarding its utility in high-risk assessment relative to the pregnancy exposure [
         <a href="#rid48">
          48
         </a>
         ]. In one study, maternal reactivity to p200 did not confer an added risk of fetal conduction defects over full-length Ro52 or Ro60 autoantibodies [
         <a href="#rid49">
          49
         </a>
         ]. Consensus has not been reached as to whether this antibody response is less often encountered in anti-Ro/SSA-exposed healthy children when all other maternal antibody reactivities to components of the Ro/SSA/La/SSB complex are equivalent. Most commercial assays do not evaluate antibody reactivity to p200.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Other factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other evidence suggests that the presence of maternal antibodies to Ro/SSA and/or La/SSB, although a powerful risk factor for CHB, is not the only determinant of the development of NL, as illustrated by the following observations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maternal antibodies to other antigens may cause neonatal disease in some cases. As an example, anti-U1 RNP (small nuclear ribonucleoprotein that associates with U1 spliceosomal RNA) antibodies in the absence of anti-Ro/SSA or anti-La/SSB antibodies were found in a few instances [
         <a href="#rid11">
          11,50
         </a>
         ]. These patients had the classic rash of NL but not advanced CHB. There is one report of transient first-degree block associated with anti-RNP absent anti-Ro/SSA-La/SSB [
         <a href="#rid51">
          51
         </a>
         ] and another of advanced block associated with anti-RNP only [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The fact that heart block develops in only a minority of subsequent pregnancies, despite the persistence of maternal anti-Ro/SSA and/or anti-La/SSB antibodies and no substantive change in titers between affected and unaffected pregnancies suggests that fetal factors are important determinants of risk. There is evidence in Japanese and European populations that fetal susceptibility to heart block may be influenced by specific human leukocyte antigen (HLA) alleles [
         <a href="#rid53">
          53,54
         </a>
         ]. HLA-DRB1*04 and HLA-Cw*05 were identified as fetal HLA allele variants conferring susceptibility to CHB, and fetal DRB1*13 and Cw*06 emerged as protective alleles in a Swedish study [
         <a href="#rid55">
          55
         </a>
         ]. However, the discordance of heart block in identical twins suggests that in utero factors in addition to genetic differences play a role [
         <a href="#rid18">
          18
         </a>
         ]. The HLA alleles DQB1*02, DRB1*03, and a polymorphism in the promoter region of the gene for tumor necrosis factor (TNF) alpha (-308A, associated with higher TNF-alpha production) are associated with skin disease [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maternal-fetal microchimerism may contribute to CHB in NL. This was illustrated in an autopsy study of hearts obtained from one fetus and three neonates who had heart block associated with maternal anti-Ro/SSA or anti-La/SSB antibodies [
         <a href="#rid57">
          57
         </a>
         ]. Female, presumably maternal, cells were found in the myocardium in all four of the males with heart block and in two of four controls, with higher numbers of female cells found in the myocardium of those with heart block.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A fetus/newborn can have either cardiac or cutaneous findings or both as the major manifestations of NL. Cardiac manifestations usually occur between 18 to 25 weeks of gestation, and the more advanced forms of heart block present as fetal bradycardia. The rash can be present at birth but more often is observed within a few weeks after birth. It can appear up to approximately four months of age. Other hepatobiliary and hematologic manifestations also may be present.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Rash
         </span>
         <span class="headingEndMark">
          —
         </span>
         The rash of NL usually comprises erythematous annular lesions or arcuate macules with slight central atrophy and raised active margins that are located primarily on the scalp and periorbital area  (
         <a class="graphic graphic_picture graphicRef111819" href="/z/d/graphic/111819.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef113334" href="/z/d/graphic/113334.html" rel="external">
          picture 2
         </a>
         ) [
         <a href="#rid58">
          58
         </a>
         ]. The periocular, scaly rash often has a raccoon-eye appearance. The atrophic lesions may be somewhat reticular and may remain even after the levels of transferred maternal antibodies have fallen. The rash is sometimes seen on other parts of the body such as the palms and soles or the diaper area [
         <a href="#rid59">
          59,60
         </a>
         ], and it is often confused with a fungal skin infection or seborrheic dermatitis. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
         The rash is noted at delivery in some cases but may not develop until after exposure to ultraviolet (UV) light, which is thought to induce or exacerbate the rash [
         <a href="#rid61">
          61
         </a>
         ]. In a cohort of 57 infants, the rash was recognized at a mean of six weeks and lasted an average of 17 weeks [
         <a href="#rid62">
          62
         </a>
         ]. The rash is usually self-limiting and almost always resolves by six to eight months of age because the half-life of immunoglobulin G (IgG) antibodies is approximately 21 to 25 days [
         <a href="#rid63">
          63
         </a>
         ]. Telangiectasia on the face or genitals occur in approximately 10 percent of patients beginning at 6 to 12 months of age [
         <a href="#rid64">
          64
         </a>
         ]. These lesions may be the only manifestation of NL or may occur in areas previously affected by the typical annular skin rash. Some studies have suggested that patients with cutaneous NL are at increased risk of developing connective tissue disease throughout their lives [
         <a href="#rid65">
          65,66
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/113264.html" rel="external">
          "Neonatal lupus: Management and outcomes", section on 'Autoimmune and/or rheumatic disease'
         </a>
         .)
        </p>
        <p>
         The histopathology of the erythematous-desquamative lesions more closely resembles that of subacute cutaneous lupus erythematosus than discoid lupus [
         <a href="#rid61">
          61
         </a>
         ]. Typical findings are vacuolar alterations at the dermoepidermal interface and adnexal structures [
         <a href="#rid67">
          67
         </a>
         ]. Some patients present with urticaria-like lesions that have superficial and deep perivascular and periadnexal lymphocytic infiltrates.
        </p>
        <p>
         Cutaneous involvement is one of the most common noncardiac manifestations of NL, affecting 4 to 16 percent of anti-Ro/SSA (Sjögren's disease type A antigen) and/or anti-La/SSB (Sjögren's disease type B antigen) antibody-exposed infants [
         <a href="#rid5">
          5-7,68
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Heart block
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with NL may develop first-, second-, and third-degree heart block. This most commonly occurs between 18 to 25 weeks of gestation. Advanced second-degree and third-degree heart block present with fetal bradycardia. Bradycardia can also occur with milder forms of second-degree block but does not occur with first-degree block. Third-degree (complete) heart block is the most serious manifestation of NL identified by echocardiogram. However, second-degree block may be more readily identified with new modalities of identification such as fetal heart rate and rhythm monitoring by home Doppler [
         <a href="#rid69">
          69
         </a>
         ]. In complete heart block, there is complete dissociation of the atrial and ventricular rates because there is no atrioventricular (AV) conduction. The atrial rate is usually normal, and the ventricular rate is typically between 50 and 80 beats per minute (bpm) but can be lower or higher. In some cases, the rate may slow as the pregnancy progresses. The clinical manifestations of complete heart block in the neonate and child are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/912.html" rel="external">
          "Congenital third-degree (complete) atrioventricular block", section on 'Clinical manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5759.html" rel="external">
          "Bradycardia in children", section on 'Atrioventricular heart block'
         </a>
         .)
        </p>
        <p>
         Fetal monitoring for development of heart block and the risk of progression from first- or second-degree heart block, particularly to complete heart block, are discussed in greater detail separately. (See
         <a class="local">
          'Fetal surveillance for heart block'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/113264.html" rel="external">
          "Neonatal lupus: Management and outcomes", section on 'First-degree heart block'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/113264.html" rel="external">
          "Neonatal lupus: Management and outcomes", section on 'Second-degree heart block'
         </a>
         .)
        </p>
        <p>
         The sinoatrial (SA) node may rarely be involved in NL [
         <a href="#rid18">
          18,70-73
         </a>
         ]. Sinus bradycardia (&lt;100 bpm) was present in 3 (3.8 percent) of 78 fetuses for whom atrial rates were recorded by echocardiogram in a series of 187 with congenital heart block (CHB) [
         <a href="#rid71">
          71
         </a>
         ]. The dysrhythmia is usually not permanent [
         <a href="#rid71">
          71
         </a>
         ] and, if sustained, carries a good prognosis if not associated with endocardial fibroelastosis (EFE), ventricular dysfunction, and/or AV nodal block [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Other cardiac abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autoantibody-mediated heart block in NL is typically associated with a structurally normal heart. However, structural abnormalities such as valvular lesions are occasionally reported [
         <a href="#rid74">
          74
         </a>
         ]. Additional cardiac abnormalities that may be associated with NL with complete heart block include congestive heart failure due to cardiomyopathy that is often associated with EFE or, on rare occasions, with myocarditis [
         <a href="#rid75">
          75
         </a>
         ]. The following observations illustrate the range of other cardiac manifestations reported in patients with NL:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Structural heart disease in association with NL is occasionally reported. However, caution is needed in interpreting such reports because some structural abnormalities may cause heart block per se (eg, L transposition of the great vessels with a single ventricle, heterotaxia, and AV septal defects). Thus, heart block in a fetus/infant with one of these structural abnormalities and exposure to maternal anti-Ro/SSA and/or anti-La/SSB antibodies may be simply due to the structural anomaly rather than NL. Of these anomalies, only ventricular septal defect (VSD) has been reported in association with NL [
         <a href="#rid76">
          76-78
         </a>
         ]. Other congenital structural cardiac anomalies observed in association with NL include persistent patent ductus arteriosus, patent foramen ovale, pulmonic stenosis, pulmonary valvular dysplasia, fusion of chordae tendineae of the tricuspid valve, and ostium secundum type atrial septal defects (ASDs) [
         <a href="#rid74">
          74,76,79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         EFE can occur in addition to conduction defects [
         <a href="#rid10">
          10,80
         </a>
         ] and has also been reported in the absence of a conduction defect in infants exposed to maternal anti-Ro/SSA and anti-La/SSB antibodies [
         <a href="#rid81">
          81,82
         </a>
         ]. In a report of 13 affected children, 7 had EFE at presentation (4 fetal and 3 postnatal), and 6 developed EFE weeks to as long as five years after the diagnosis of CHB [
         <a href="#rid80">
          80
         </a>
         ]. Nine patients died, and two underwent cardiac transplantation because of the EFE. (See
         <a class="medical medical_review" href="/z/d/html/4943.html" rel="external">
          "Definition and classification of the cardiomyopathies", section on 'Endocardial fibroelastosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There are a few reported cases of suspected myocarditis (with cardiomegaly and moderate mitral and tricuspid valvular regurgitation in one patient and sudden death in another) in association with NL and CHB [
         <a href="#rid77">
          77,83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aortic dilation is associated with maternal anti-Ro/SSA antibodies. In a large series of over 200 children exposed to these antibodies, aortic dilation was present on echocardiogram in 13.5 percent of studies performed in the first year of life, 15 percent evaluated at &gt;1 to 17 years of age, and in 9.4 percent tested at &gt;17 years of age [
         <a href="#rid84">
          84
         </a>
         ]. Some patients had new-onset aortic dilation after a previously normal echocardiogram. Thus, monitoring for late effects is recommended. The aortic dilation seen in cardiac NL is felt to be an epiphenomenon in the presence of chronic bradycardia and increased stroke volumes that result from poor contractility, with documented improvement after initiation of dual-chamber pacing [
         <a href="#rid85">
          85,86
         </a>
         ]. There are no reports of aortic dilation in cardiac NL leading to aortic dissection or progressing to the point of requiring aortic surgery.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4188537167">
         <span class="h2">
          Pulmonary hypertension
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a French registry, 4 of 73 anti-Ro-exposed neonates developed pulmonary hypertension. Diagnosis was suspected on transthoracic echocardiography at a median age of 42 days and confirmed by right heart catheterization. Lung computed tomography (CT) demonstrated ground glass anomalies in all. Management included immunosuppressive therapy in three and additional
         <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">
          sildenafil
         </a>
         in two. Pulmonary hypertension resolved in all at a median age of four weeks after treatment initiation and after one year for the one child who did not receive specific treatment [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Other manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to rash and cardiac abnormalities, there may be transient hepatic, hematologic, neurologic, or radiologic manifestations of NL [
         <a href="#rid63">
          63
         </a>
         ]. Hydrops fetalis, a complication of NL due to cardiac injury, is seen in some fetuses with complete heart block [
         <a href="#rid1">
          1,88
         </a>
         ]. It is a condition of excess fluid accumulation in the fetus that can result in fetal demise and is a poor prognostic sign.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatic manifestations include asymptomatic elevated liver enzymes, mild hepatosplenomegaly, cholestasis, and hepatitis [
         <a href="#rid61">
          61,89,90
         </a>
         ]. In one report, hepatobiliary disease occurred in 19 of 219 infants (9 percent) with NL, usually in conjunction with either cardiac or cutaneous involvement [
         <a href="#rid91">
          91
         </a>
         ]. In another series of 54 infants with NL, 15 percent had transiently elevated transaminase levels [
         <a href="#rid92">
          92
         </a>
         ]. Elevated liver enzymes can persist beyond six months [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hematologic manifestations also have been described, including anemia, neutropenia, thrombocytopenia, and, rarely, aplastic anemia [
         <a href="#rid5">
          5,61,89,90,92,94-97
         </a>
         ]. The published literature suggests a range from 0 to 27 percent, with the more characteristic abnormality being low neutrophils. However, the true frequencies of hematologic manifestations is not known, since a complete blood count is not normally performed on otherwise healthy babies [
         <a href="#rid96">
          96-98
         </a>
         ]. Neutropenia was present in 25 of 107 tested infants born to mothers with anti-Ro/SSA or anti-La/SSB antibodies in one prospective study, but no cases of neonatal sepsis occurred in these neutropenic children [
         <a href="#rid5">
          5
         </a>
         ]. In a prospective study of 50 infants exposed to anti-Ro/SSA in utero, 1 (2 percent) had low platelets at birth, and 2 (4 percent) had low neutrophils. By three months of life, none had low platelets, but the number of infants with low neutrophils had risen to 12 (24 percent) [
         <a href="#rid78">
          78
         </a>
         ]. However, an earlier prospective study of 51 anti-Ro/SSA-exposed infants found no cases of neutropenia, lymphopenia, or anemia; while two of the infants (3.9 percent) had thrombocytopenia, these cases may have been caused by other antiplatelet autoantibodies [
         <a href="#rid79">
          79
         </a>
         ]. When limited only to anti-Ro/SSA and/or anti-La/SSB females with a diagnosed connective tissue disease, 219 prospectively evaluated pregnancies resulted in infants with 33 (15 percent) cases of cutaneous NL, 41 (18.7 percent) cases of neutropenia, and 3 (1.4 percent) cases of thrombocytopenia [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neurologic manifestations have been described [
         <a href="#rid61">
          61
         </a>
         ], but whether there is an association with anti-Ro/SSA antibodies is uncertain. In one study, 7 of 87 infants exposed to maternal Ro/SSA were reported to have hydrocephalus, and 10 had macrocephaly [
         <a href="#rid99">
          99
         </a>
         ]. These findings have not been reported in other cohorts of anti-Ro/SSA-exposed children. In a study from New York, there was a trend toward higher parental reporting of neuropsychiatric dysfunction in children with NL compared with normal friend controls [
         <a href="#rid100">
          100
         </a>
         ]. Based upon a systematic literature review, most reported neonates considered to have NL with central nervous system involvement were identified by neuroimaging and were asymptomatic. Only seven cases (most associated with rash and none with CHB) were considered symptomatic by virtue of having a physical disability or requiring neurosurgery [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A unique radiographic finding of NL is stippling of the epiphyses (chondrodysplasia punctata) [
         <a href="#rid61">
          61
         </a>
         ]. It generally resolves without treatment within the first year of life.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of NL is made when the following are both present:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The mother or the affected child (if the mother is not tested for some reason, even though maternal testing is indicated) has anti-Ro/SSA (Sjögren's disease type A antigen) and/or anti-La/SSB (Sjögren's disease type B antigen) or possibly anti-ribonucleoprotein (RNP) antibodies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The fetus or newborn develops heart block, or the newborn develops the typical rash or hepatic or hematologic manifestations in the absence of another explanation. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2613395010">
         <span class="h1">
          SCREENING AND SURVEILLANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following recommendations for pre- and postnatal screening and surveillance are based upon the potential cardiac manifestations of NL and their associated morbidity and mortality.
        </p>
        <p class="headingAnchor" id="H637072611">
         <span class="h2">
          Prenatal
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prenatal evaluation includes maternal screening for anti-Ro/SSA (Sjögren's disease type A antigen) and anti-La/SSB (Sjögren's disease type B antigen) antibodies and in utero surveillance for heart block.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Maternal screening
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prenatal screening for anti-Ro/SSA and anti-La/SSB antibodies is warranted for individuals at risk of having a pregnancy complicated by NL. Individuals who are more likely to have anti-Ro/SSA and anti-La/SSB antibodies include those with systemic lupus erythematosus (SLE), Sjögren's disease, rheumatoid arthritis, mixed connective tissue disease, an undifferentiated autoimmune disease, or NL with cutaneous and/or cardiac manifestations in a previous pregnancy. Individuals with these identifiable risk factors should be tested before conception or as early in pregnancy as possible. Although many of these individuals will have previously been tested and presence or absence of these antibodies is unlikely to change over time, the cautious approach is to recheck when pregnancy is confirmed. Routine screening of all pregnant persons for anti-Ro/SSA and anti-La/SSB antibodies is not performed, but this may change if preventive therapies are validated. (See
         <a class="medical medical_review" href="/z/d/html/4679.html" rel="external">
          "Pregnancy in women with systemic lupus erythematosus"
         </a>
         .)
        </p>
        <p>
         Maternal testing for anti-Ro/SSA and anti-La/SSB antibodies is also indicated if there is detection of a slow fetal heart rate and subsequent echocardiographic confirmation of heart block, even in an asymptomatic individual, since NL in a fetus can be the first sign that the mother has anti-Ro/SSA and/or anti-La/SSB antibodies. (See
         <a class="local">
          'Autoantibodies'
         </a>
         above.)
        </p>
        <p>
         With regard to antibody testing, titer is highly relevant for reasons related to both underlying pathology and clinical management. Given the identification of fetal injury in the middle to late second trimester, it is pertinent that neonatal Fc receptor (FcRn) mediated placental transport of maternal IgG at this timepoint in gestation is only a fraction of the efficiency achieved at term [
         <a href="#rid102">
          102
         </a>
         ]. This biology predicts that cardiac injury during the gestation period of fetal vulnerability should require very high titers of antibody.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A US-based study examined the negative predictive value of antibody titers to identify pregnancies at low risk of fetal atrioventricular (AV) block that may not require surveillance [
         <a href="#rid42">
          42
         </a>
         ]. Excluding females with previously affected children and leveraging samples obtained from anti-SSA/Ro-exposed pregnancies with and without congenital heart block (CHB), no case of block developed among subjects with anti-Ro52 and anti-Ro60 titers of &lt;110 arbitrary units per milliliter using the multiplex bead assay of the Associated Regional and University Pathologists Laboratories (n = 141). Applying these 100 percent negative predictive value thresholds, approximately 50 percent of the anti-Ro/SSA antibody pregnancies that ultimately had no CHB could be excluded from surveillance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a report from Canada of a prospectively followed cohort of 240 mothers, none of 14 negative for anti-Ro60 or 93 with levels considered positive but lower than the upper limit of the analytic measuring range of a commercial assay available in Toronto had a child with CHB [
         <a href="#rid23">
          23
         </a>
         ]. In contrast, of 133 mothers with "high" positive anti-Ro60 antibodies exceeding the analytical measuring range, nine cases (7 percent) developed CHB. Extended evaluation of 122 mothers with further dilutions revealed that risk increased for those in the uppermost range for anti-Ro60, reaching 29 percent (6/21) and 56 percent (5/9) for the highest range obtained for both anti-Ro52 and Ro60, both rates higher than previously reported recurrence rates.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective study of over 400 anti-Ro positive pregnancies is underway (Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly;
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT04474223&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSwlqlY0fg6ie%2FCVR%2Fmg%2FKVSwGWY7FnIY1Fv4mtd5yFBQQ%3D%3D&amp;TOPIC_ID=6402" target="_blank">
          NCT04474223
         </a>
         ), and early unpublished data confirm that low anti-Ro/SSA titer does not pose risk and that high titer (top quartile of both the anti-Ro60 and 52 assays) confers an 8 percent risk if there is no history of a previously affected child [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4219179">
         <span class="h3">
          Fetal surveillance for heart block
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recommendations regarding monitoring during pregnancies exposed to anti-Ro/SSA have varied, but most agree the driving rationale is that detection of heart block at earlier stages should improve outcomes [
         <a href="#rid104">
          104-106
         </a>
         ]. Although persons with low titer antibodies are less likely to have offspring with cardiac-NL than those with high titers [
         <a href="#rid37">
          37,40,41,49
         </a>
         ], in practical terms, this is difficult to implement in the clinical setting because commercial laboratories have different cutoff values. Nevertheless, values &lt;8 enzyme-linked immunosorbent assay (ELISA) units in commercial laboratories that use the immunoassay discussed above (see
         <a class="local">
          'Autoantibodies'
         </a>
         above) may not warrant intense serial surveillance. The most vulnerable period for the fetus is during gestational weeks 18 to 25 [
         <a href="#rid7">
          7
         </a>
         ]. Normal sinus rhythm (NSR) can progress to complete block in seven days during this high-risk period and even within 24 hours as detected by home Doppler [
         <a href="#rid69">
          69
         </a>
         ]. New onset of heart block is less likely to develop during the 26
         <sup>
          th
         </sup>
         through the 30
         <sup>
          th
         </sup>
         week, and it rarely develops after 30 weeks of pregnancy.
        </p>
        <p>
         Second-degree atrioventricular block (2° AVB) is potentially reversible based upon a meta-analysis [
         <a href="#rid107">
          107
         </a>
         ] of five studies [
         <a href="#rid1">
          1,88,108-110
         </a>
         ] in which overall regression to NSR was reported in 24 percent regardless of therapy. Another study of 21 cases of 2° AVB revealed three regressing to NSR [
         <a href="#rid111">
          111
         </a>
         ]. Of these, one had received
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         , and the other two regressed spontaneously (however, one mother was seronegative).
        </p>
        <p>
         Many experts in the field advise performing weekly pulsed-Doppler fetal echocardiography (measures the mechanical PR interval from the onset of atrial contraction [initiation of mitral valve movement] to ventricular contraction [aortic pulsation]) from the 18
         <sup>
          th
         </sup>
         through the 26
         <sup>
          th
         </sup>
         week of pregnancy [
         <a href="#rid112">
          112
         </a>
         ]. The American Heart Association suggests a few additional weeks of serial assessment, starting at 16 weeks and continuing through 28 weeks of gestation [
         <a href="#rid104">
          104
         </a>
         ]. Echocardiography enables the diagnosis of first-degree heart block and second-degree block that does not manifest as fetal bradycardia, as well as endocardial fibroelastosis or more serious valvular disease, that would not be picked up on examination with the standard handheld continuous Doppler ultrasound device that measures the fetal heart rate but does not supply an image [
         <a href="#rid105">
          105,113,114
         </a>
         ]. However, fetal atrioventricular intervals were not predictive of progression of heart block in one small study [
         <a href="#rid115">
          115
         </a>
         ].
        </p>
        <p>
         Controversy regarding fetal surveillance has escalated with the publication of a consensus statement by the Society for Maternal-Fetal Medicine (SMFM) recommending that serial fetal echocardiograms for assessment of the PR interval
         <strong>
          not
         </strong>
         be routinely performed in patients with anti-SSA/SSB antibodies outside of a clinical trial setting, since the scientific rigor of the data remain insufficient and treatment is not convincingly effective [
         <a href="#rid116">
          116
         </a>
         ]. This statement was criticized in a rebuttal letter from many pediatric cardiologists and rheumatologists [
         <a href="#rid117">
          117
         </a>
         ] pointing out that this statement differed from that of the American College of Rheumatology (ACR) Reproductive Health Guideline, which conditionally recommends fetal echocardiograms, recognizing that this area is controversial, and that risks and benefits should be discussed with the patient in a shared decision-making process [
         <a href="#rid118">
          118
         </a>
         ].
        </p>
        <p>
         Complete heart block (and usually second-degree block) results in fetal bradycardia that can be detected by routine fetal auscultation. An emerging approach that is inexpensive and that empowers the mother to take part in their own pregnancy surveillance is home fetal heart rate and rhythm monitoring (FHRM), which can be used in combination with surveillance echocardiography weekly or every two weeks [
         <a href="#rid69">
          69
         </a>
         ]. While reported studies have only evaluated twice-daily home monitoring, thrice-daily monitoring is also an option and is under study (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04474223&amp;token=nbsXe3i4qfUea5RCPRHtOY5G%2FPzFIESeuM6wIJ4nJiQK5ilS9VROvZa27ScACX5Iqhcp6jJCjw1uRnq1xswSCA%3D%3D&amp;TOPIC_ID=6402" target="_blank">
          NCT04474223
         </a>
         ). Early detection of a transition from NSR to incomplete block may represent the most optimal time for intervention to make a difference. No false-negative results with the home Doppler were reported, supporting that the Doppler did not miss a clinically meaningful abnormality that was later identified by echocardiogram. Moreover, the false-positive rates were likewise low. Further studies are ongoing in this emerging area of surveillance. (See
         <a class="local">
          'Heart block'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6765.html" rel="external">
          "Fetal arrhythmias", section on 'Modalities for diagnostic evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4219069">
         <span class="h2">
          Postnatal testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Testing for maternal anti-Ro/SSA antibodies should be performed in the mother of any neonate with heart block and no identified causal structural abnormalities because these antibodies account for 80 to 95 percent of reported cases of CHB in the fetus and neonate [
         <a href="#rid9">
          9,10
         </a>
         ]. Infants up to eight months of age with an annular or polycyclic rash and/or any degree of heart block (although de novo development of CHB after birth is extraordinarily rare and may indeed represent evolved first- or second-degree block missed in utero) should also be tested for maternally derived anti-Ro/SSA and anti-La/SSB antibodies. A positive test in the child or mother fulfills the diagnostic criteria for NL.
        </p>
        <p class="headingAnchor" id="H4219076">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H3176055660">
         <span class="h2">
          Rash without heart block
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis for NL rash includes various rashes seen in the newborn period. These other rashes are not associated with congenital heart block (CHB) or with maternal anti-Ro/SSA (Sjögren's disease type A antigen), anti-La/SSB (Sjögren's disease type B antigen), or anti-ribonucleoprotein (RNP) antibodies.
        </p>
        <p>
         The differential diagnosis of isolated polycyclic skin lesions in a newborn or neonate includes the following diseases [
         <a href="#rid119">
          119
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Urticaria
         </strong>
         – Urticarial lesions are intensely itchy, circumscribed, raised, erythematous plaques, often with central pallor  (
         <a class="graphic graphic_picture graphicRef78544" href="/z/d/graphic/78544.html" rel="external">
          picture 3
         </a>
         ). Unlike NL rash, the center of an urticarial lesion is usually raised rather than atrophied. In addition, individual urticaria lesions are transient, disappearing within 24 hours. (See
         <a class="medical medical_review" href="/z/d/html/8101.html" rel="external">
          "New-onset urticaria"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Urticaria multiforme (acute annular urticaria) is a self-limited urticarial hypersensitivity eruption that primarily occurs in infants and very young children. Lesions appear on the face, trunk, and extremities as annular erythematous plaques with central clearing or dusky-blue centers. Unlike NL, the duration of individual lesions does not exceed 24 hours, and pruritus is typically present. (See
         <a class="medical medical_review" href="/z/d/html/13690.html" rel="external">
          "Approach to the patient with annular skin lesions", section on 'Migratory or transient lesions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tinea corporis
         </strong>
         – Tinea corporis often begins as a pruritic, circular or oval, erythematous, scaling patch or plaque that spreads centrifugally  (
         <a class="graphic graphic_picture graphicRef55949" href="/z/d/graphic/55949.html" rel="external">
          picture 4
         </a>
         ). Central clearing follows, while an active, advancing, raised border remains. Unlike tinea corporis, scale is absent in NL rash, and no fungal hyphae are seen on a potassium hydroxide (KOH) preparation of skin scrapings. (See
         <a class="medical medical_review" href="/z/d/html/4030.html" rel="external">
          "Dermatophyte (tinea) infections", section on 'Tinea corporis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Seborrheic dermatitis
         </strong>
         – While the most common manifestation of seborrheic dermatitis in newborns and infants is "cradle cap," an asymptomatic and noninflammatory accumulation of yellowish, greasy scales on the scalp, sometimes the eruption starts on the face, with erythematous, scaly, salmon-colored plaques  (
         <a class="graphic graphic_picture graphicRef101269" href="/z/d/graphic/101269.html" rel="external">
          picture 5
         </a>
         ). The NL rash is more purpuric in color, and the scaling is less prominent. (See
         <a class="medical medical_review" href="/z/d/html/16261.html" rel="external">
          "Cradle cap and seborrheic dermatitis in infants"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Annular erythemas of childhood
         </strong>
         – These are rare, poorly defined diseases with similar names, including erythema annulare centrifugum  (
         <a class="graphic graphic_picture graphicRef59741" href="/z/d/graphic/59741.html" rel="external">
          picture 6
         </a>
         and
         <a class="graphic graphic_picture graphicRef80998" href="/z/d/graphic/80998.html" rel="external">
          picture 7
         </a>
         ), familial annular erythema [
         <a href="#rid120">
          120
         </a>
         ], erythema multiforme  (
         <a class="graphic graphic_picture graphicRef79955" href="/z/d/graphic/79955.html" rel="external">
          picture 8
         </a>
         and
         <a class="graphic graphic_picture graphicRef68640" href="/z/d/graphic/68640.html" rel="external">
          picture 9
         </a>
         and
         <a class="graphic graphic_picture graphicRef51037" href="/z/d/graphic/51037.html" rel="external">
          picture 10
         </a>
         ), and annular erythema of infancy [
         <a href="#rid121">
          121
         </a>
         ]. They can be distinguished from NL by their migrating course, presence of peripheral lesions, a scaly border with erythema, lack of atrophy, disappearance of individual lesions after days to weeks with subsequent appearance of new lesions elsewhere, and a long-lasting course (usually beyond six months). (See
         <a class="medical medical_review" href="/z/d/html/5559.html" rel="external">
          "Erythema multiforme: Pathogenesis, clinical features, and diagnosis", section on 'Clinical manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4030.html" rel="external">
          "Dermatophyte (tinea) infections", section on 'Tinea corporis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cutis marmorata telangiectasia congenita (CMTC)
         </strong>
         – These lesions can be confused with the reticular, atrophic lesions of NL [
         <a href="#rid122">
          122
         </a>
         ]. However, CMTC lesions most commonly affect the limbs, particularly the lower extremities, and are usual unilateral. The affected limb can become discrepant in size and shape. Lesions resolve more slowly than in NL, usually within two years. (See
         <a class="medical medical_review" href="/z/d/html/5789.html" rel="external">
          "Vascular lesions in the newborn", section on 'Cutis marmorata telangiectatica congenita'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Langerhans cell histiocytosis (LCH)
         </strong>
         – Infants with LCH may present with brown to purplish papules with a purpuric hue similar to that of NL rash. Alternatively, patients with LCH may present with an eczematous rash resembling a candidal infection and seborrheic involvement of the scalp. Other skin lesions may be pustular, purpuric, petechial, vesicular, or papulonodular. Over half of patients who present with rashes are determined to have multisystem disease (including liver, spleen, lung, bone, bone marrow, lymph nodes, and central nervous system) upon further evaluation. LCH can be distinguished histologically and immunophenotypically from NL based upon skin biopsy evaluation. (See
         <a class="medical medical_review" href="/z/d/html/8385.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Autoinflammatory syndromes
         </strong>
         – Some autoinflammatory diseases that closely resemble lupus erythematosus can begin during the neonatal period. These include stimulator of interferon genes (STING) associated vasculopathy with onset in infancy (SAVI), chronic atypical neutrophilic dermatitis with lipodystrophy and elevated temperature syndrome (CANDLE syndrome), autoinflammation and PLCG2-associated antibody deficiency and immune dysregulation (APLAID), and C1q deficiency. Most of these patients present with fever and/or have multisystem involvement unlike NL. (See
         <a class="medical medical_review" href="/z/d/html/5597.html" rel="external">
          "The autoinflammatory diseases: An overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3962.html" rel="external">
          "Inherited disorders of the complement system", section on 'C1 deficiency'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1618863806">
         <span class="h2">
          Fetal bradycardia/heart block
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common causes of fetal bradycardia, in the absence of labor, are complete heart block, sinus bradycardia, and blocked atrial bigeminy. NL is the most common cause of CHB in the fetus/newborn, but CHB can also result from congenital heart defects. In addition, there is an idiopathic familial form of CHB. The etiology and differential diagnosis of complete CHB and the causes of fetal bradycardia are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/912.html" rel="external">
          "Congenital third-degree (complete) atrioventricular block", section on 'Etiology'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/912.html" rel="external">
          "Congenital third-degree (complete) atrioventricular block", section on 'Differential diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6765.html" rel="external">
          "Fetal arrhythmias", section on 'Bradyarrhythmias'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2792079554">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – Neonatal lupus (NL) is a passively acquired autoimmune disease that occurs in offspring of mothers with anti-Ro/SSA (Sjögren's disease type A antigen) and/or anti-La/SSB (Sjögren's disease type B antigen) antibodies. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk of NL with congenital heart block
         </strong>
         – The risk of having a child with congenital heart block (CHB) in these mothers is approximately 2 percent for first pregnancies or if previous babies were healthy. The risk increases approximately 10- and 5-fold, respectively, if a previous child had complete heart block or cutaneous NL. While prospective confirmation awaits, individuals with titers of anti-Ro/SSA antibodies that are considered "low" may not be at risk for CHB, and risk seems to increase as titer increases. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – The primary clinical features are heart block and a rash that is usually found on the scalp and periorbital areas  (
         <a class="graphic graphic_picture graphicRef111819" href="/z/d/graphic/111819.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef113334" href="/z/d/graphic/113334.html" rel="external">
          picture 2
         </a>
         ). Patients may also present after birth with hepatic or hematologic abnormalities. The large majority of cases of congenital heart block without major structural abnormalities that are diagnosed in utero or in the neonatal period are associated with maternal anti-Ro/SSA antibodies. Cardiomyopathy can occur in isolation or more commonly with heart block and is associated with an increased risk of fetal/neonatal demise. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/912.html" rel="external">
          "Congenital third-degree (complete) atrioventricular block"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of NL is made when the following are both present (see
         <a class="local">
          'Diagnosis'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The mother has anti-Ro/SSA, anti-La/SSB, or possibly anti-ribonucleoprotein (RNP) antibodies (in the case of cutaneous disease).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The fetus or newborn develops heart block, or the newborn develops the typical rash or hepatic or hematologic manifestations in the absence of another explanation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fetal surveillance for heart block
         </strong>
         – While there is not uniform consensus in the recommendations provided by societies representing maternal fetal medicine, pediatric cardiology, and rheumatology, biweekly or weekly fetal echocardiography from the 18
         <sup>
          th
         </sup>
         through the 26
         <sup>
          th
         </sup>
         week of pregnancy is often advised in females with anti-Ro/SSA and/or anti-La/SSB antibodies (albeit anti-La/SSB antibodies are extremely rare in isolation without anti-Ro/SSA), regardless of health status. Previous recommendations for weekly echocardiographic surveillance included every other week testing after 26 weeks to 32 weeks. However, the rarity of de novo heart block after 26 weeks has raised questions as to the necessity of such rigorous monitoring. For females with "low" titers of antibodies (definition of which varies with different laboratories), surveillance may not be needed at all. Frequent Doppler monitoring by the pregnant female may identify earlier (incomplete block), potentially reversible disease. (See
         <a class="local">
          'Fetal surveillance for heart block'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maternal screening for anti-Ro/SSA and La/SSB antibodies
         </strong>
         – The detection of a slow fetal heart rate and subsequent echocardiographic confirmation of heart block or postnatal diagnosis of heart block and no identified causal structural abnormalities, even in an asymptomatic female, warrants immediate maternal testing for anti-Ro/SSA and La/SSB antibodies if not previously performed. In addition, a periorbital rash in an infant less than six months warrants antibody testing in the mother. (See
         <a class="local">
          'Maternal screening'
         </a>
         above and
         <a class="local">
          'Postnatal testing'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Izmirly PM, Saxena A, Kim MY, et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation 2011; 124:1927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Izmirly PM, Saxena A, Sahl SK, et al. Assessment of fluorinated steroids to avert progression and mortality in anti-SSA/Ro-associated cardiac injury limited to the fetal conduction system. Ann Rheum Dis 2016; 75:1161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brucato A, Cimaz R, Caporali R, et al. Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies. Clin Rev Allergy Immunol 2011; 40:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brucato A, Frassi M, Franceschini F, et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 2001; 44:1832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cimaz R, Spence DL, Hornberger L, Silverman ED. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr 2003; 142:678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Costedoat-Chalumeau N, Amoura Z, Lupoglazoff JM, et al. Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group. Arthritis Rheum 2004; 50:3187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman DM, Kim MY, Copel JA, et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation 2008; 117:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brito-Zerón P, Izmirly PM, Ramos-Casals M, et al. The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol 2015; 11:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buyon JP, Clancy RM, Friedman DM. Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside. Nat Clin Pract Rheumatol 2009; 5:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaeggi ET, Hamilton RM, Silverman ED, et al. Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. A single institution's experience of 30 years. J Am Coll Cardiol 2002; 39:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Provost TT, Watson R, Gammon WR, et al. The neonatal lupus syndrome associated with U1RNP (nRNP) antibodies. N Engl J Med 1987; 316:1135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rivera TL, Izmirly PM, Birnbaum BK, et al. Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus. Ann Rheum Dis 2009; 68:828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fritzler MJ, Pauls JD, Kinsella TD, Bowen TJ. Antinuclear, anticytoplasmic, and anti-Sjogren's syndrome antigen A (SS-A/Ro) antibodies in female blood donors. Clin Immunol Immunopathol 1985; 36:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Satoh M, Chan EK, Ho LA, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 2012; 64:2319.
          </a>
         </li>
         <li class="breakAll">
          Keogan M, Kearns G, Jefferies CA. Extractable nuclear antigens and SLE: Specificity and role in disease pathogenesis. In: Systemic Lupus Erythematosus, 5th ed., Lahita RG, Tsokos G, Buyon J, Koike T (Eds), Academic Press, San Diego 2011. p.259.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sirén MK, Julkunen H, Kaaja R. The increasing incidence of isolated congenital heart block in Finland. J Rheumatol 1998; 25:1862.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Llanos C, Izmirly PM, Katholi M, et al. Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum 2009; 60:3091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buyon JP, Kim MY, Copel JA, Friedman DM. Anti-Ro/SSA antibodies and congenital heart block: necessary but not sufficient. Arthritis Rheum 2001; 44:1723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michaëlsson M, Engle MA. Congenital complete heart block: an international study of the natural history. Cardiovasc Clin 1972; 4:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Izmirly PM, Llanos C, Lee LA, et al. Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. Arthritis Rheum 2010; 62:1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012; 126:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miniaoui I, Morel N, Lévesque K, et al. Health Outcomes of 215 Mothers of Children With Autoimmune Congenital Heart Block: Analysis of the French Neonatal Lupus Syndrome Registry. J Rheumatol 2022; 49:1124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaeggi E, Kulasingam V, Chen J, et al. Maternal Anti-Ro Antibody Titers Obtained With Commercially Available Immunoassays Are Strongly Associated With Immune-Mediated Fetal Heart Disease. Arthritis Rheumatol 2023; 75:1556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clancy RM, Neufing PJ, Zheng P, et al. Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block. J Clin Invest 2006; 116:2413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miranda-Carús ME, Askanase AD, Clancy RM, et al. Anti-SSA/Ro and anti-SSB/La autoantibodies bind the surface of apoptotic fetal cardiocytes and promote secretion of TNF-alpha by macrophages. J Immunol 2000; 165:5345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clancy R, Molad Y, Kapur R, et al. Histologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathogenesis of congenital heart block (abstract). Arthritis Rheum 2002; 46:S394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clancy RM, Askanase AD, Kapur RP, et al. Transdifferentiation of cardiac fibroblasts, a fetal factor in anti-SSA/Ro-SSB/La antibody-mediated congenital heart block. J Immunol 2002; 169:2156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia S, Nascimento JH, Bonfa E, et al. Cellular mechanism of the conduction abnormalities induced by serum from anti-Ro/SSA-positive patients in rabbit hearts. J Clin Invest 1994; 93:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xiao GQ, Hu K, Boutjdir M. Direct inhibition of expressed cardiac l- and t-type calcium channels by igg from mothers whose children have congenital heart block. Circulation 2001; 103:1599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karnabi E, Qu Y, Mancarella S, Boutjdir M. Rescue and worsening of congenital heart block-associated electrocardiographic abnormalities in two transgenic mice. J Cardiovasc Electrophysiol 2011; 22:922.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strandberg LS, Cui X, Rath A, et al. Congenital heart block maternal sera autoantibodies target an extracellular epitope on the α1G T-type calcium channel in human fetal hearts. PLoS One 2013; 8:e72668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markham AJ, Rasmussen SE, Salmon JE, et al. Reactivity to the p305 Epitope of the α1G T-Type Calcium Channel and Autoimmune-Associated Congenital Heart Block. J Am Heart Assoc 2015; 4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suryawanshi H, Clancy R, Morozov P, et al. Cell atlas of the foetal human heart and implications for autoimmune-mediated congenital heart block. Cardiovasc Res 2020; 116:1446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clancy RM, Halushka M, Rasmussen SE, et al. Siglec-1 Macrophages and the Contribution of IFN to the Development of Autoimmune Congenital Heart Block. J Immunol 2019; 202:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ivanchenko M, Thorlacius GE, Hedlund M, et al. Natural killer cells and type II interferon in Ro/SSA and La/SSB autoantibody-exposed newborns at risk of congenital heart block. Ann Rheum Dis 2021; 80:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Firl CEM, Halushka M, Fraser N, et al. Contribution of S100A4-expressing fibroblasts to anti-SSA/Ro-associated atrioventricular nodal calcification and soluble S100A4 as a biomarker of clinical severity. Front Immunol 2023; 14:1114808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buyon JP, Winchester RJ, Slade SG, et al. Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. Comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti-SS-A/Ro and anti-SS-B/La antibodies. Arthritis Rheum 1993; 36:1263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buyon J, Roubey R, Swersky S, et al. Complete congenital heart block: risk of occurrence and therapeutic approach to prevention. J Rheumatol 1988; 15:1104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon P, Khamashta MA, Rosenthal E, et al. Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. J Rheumatol 2004; 31:2480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaeggi E, Laskin C, Hamilton R, et al. The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus a prospective study of 186 antibody-exposed fetuses and infants. J Am Coll Cardiol 2010; 55:2778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kan N, Silverman ED, Kingdom J, et al. Serial echocardiography for immune-mediated heart disease in the fetus: results of a risk-based prospective surveillance strategy. Prenat Diagn 2017; 37:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaizer AM, Lindblade C, Clancy R, et al. Reducing the burden of surveillance in pregnant women with no history of fetal atrioventricular block using the negative predictive value of anti-Ro/SSA antibody titers. Am J Obstet Gynecol 2022; 227:761.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stea EA, Routsias JG, Clancy RM, et al. Anti-La/SSB antiidiotypic antibodies in maternal serum: a marker of low risk for neonatal lupus in an offspring. Arthritis Rheum 2006; 54:2228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reed JH, Jackson MW, Gordon TP. A B cell apotope of Ro 60 in systemic lupus erythematosus. Arthritis Rheum 2008; 58:1125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fritsch C, Hoebeke J, Dali H, et al. 52-kDa Ro/SSA epitopes preferentially recognized by antibodies from mothers of children with neonatal lupus and congenital heart block. Arthritis Res Ther 2006; 8:R4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salomonsson S, Sonesson SE, Ottosson L, et al. Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. J Exp Med 2005; 201:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strandberg L, Winqvist O, Sonesson SE, et al. Antibodies to amino acid 200-239 (p200) of Ro52 as serological markers for the risk of developing congenital heart block. Clin Exp Immunol 2008; 154:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clancy RM, Buyon JP, Ikeda K, et al. Maternal antibody responses to the 52-kd SSA/RO p200 peptide and the development of fetal conduction defects. Arthritis Rheum 2005; 52:3079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reed JH, Clancy RM, Lee KH, et al. Umbilical cord blood levels of maternal antibodies reactive with p200 and full-length Ro 52 in the assessment of risk for cardiac manifestations of neonatal lupus. Arthritis Care Res (Hoboken) 2012; 64:1373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheth AP, Esterly NB, Ratoosh SL, et al. U1RNP positive neonatal lupus erythematosus: association with anti-La antibodies? Br J Dermatol 1995; 132:520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Acherman RJ, Friedman DM, Buyon JP, et al. Doppler fetal mechanical PR interval prolongation with positive maternal anti-RNP but negative SSA/Ro and SSB/La auto-antibodies. Prenat Diagn 2010; 30:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Izmirly PM, Halushka MK, Rosenberg AZ, et al. Clinical and pathologic implications of extending the spectrum of maternal autoantibodies reactive with ribonucleoproteins associated with cutaneous and now cardiac neonatal lupus from SSA/Ro and SSB/La to U1RNP. Autoimmun Rev 2017; 16:980.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sirén MK, Julkunen H, Kaaja R, et al. Role of HLA in congenital heart block: susceptibility alleles in children. Lupus 1999; 8:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clancy RM, Marion MC, Kaufman KM, et al. Identification of candidate loci at 6p21 and 21q22 in a genome-wide association study of cardiac manifestations of neonatal lupus. Arthritis Rheum 2010; 62:3415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meisgen S, Östberg T, Salomonsson S, et al. The HLA locus contains novel foetal susceptibility alleles for congenital heart block with significant paternal influence. J Intern Med 2014; 275:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clancy RM, Backer CB, Yin X, et al. Genetic association of cutaneous neonatal lupus with HLA class II and tumor necrosis factor alpha: implications for pathogenesis. Arthritis Rheum 2004; 50:2598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens AM, Hermes HM, Rutledge JC, et al. Myocardial-tissue-specific phenotype of maternal microchimerism in neonatal lupus congenital heart block. Lancet 2003; 362:1617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shiiya C, Ota M. Facial Rash, Fever, and Anemia in a Newborn. JAMA 2017; 317:2125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sommer LL, Manders SM. Seeing double: annular diaper rash in twins. Pediatr Dermatol 2015; 32:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           See A, Wargon O, Lim A, et al. Neonatal lupus erythematosus presenting as papules on the feet. Australas J Dermatol 2005; 46:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silverman E, Jaeggi E. Non-cardiac manifestations of neonatal lupus erythematosus. Scand J Immunol 2010; 72:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neiman AR, Lee LA, Weston WL, Buyon JP. Cutaneous manifestations of neonatal lupus without heart block: characteristics of mothers and children enrolled in a national registry. J Pediatr 2000; 137:674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee LA. Neonatal lupus: clinical features, therapy, and pathogenesis. Curr Rheumatol Rep 2001; 3:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guinovart RM, Vicente A, Rovira C, et al. Facial telangiectasia: an unusual manifestation of neonatal lupus erythematosus. Lupus 2012; 21:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin V, Lee LA, Askanase AD, et al. Long-term followup of children with neonatal lupus and their unaffected siblings. Arthritis Rheum 2002; 46:2377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garza Romero A, Izmirly PM, Ainsworth HC, et al. Development of autoimmune diseases and genetic predisposition in children with neonatal lupus and their unaffected siblings [abstract]. Arthritis Rheumatol 2016; 68(Suppl 10).
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peñate Y, Guillermo N, Rodríguez J, et al. Histopathologic characteristics of neonatal cutaneous lupus erythematosus: description of five cases and literature review. J Cutan Pathol 2009; 36:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barsalou J, Costedoat-Chalumeau N, Berhanu A, et al. Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus. Ann Rheum Dis 2018; 77:1742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cuneo BF, Sonesson SE, Levasseur S, et al. Home Monitoring for Fetal Heart Rhythm During Anti-Ro Pregnancies. J Am Coll Cardiol 2018; 72:1940.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho SY, Esscher E, Anderson RH, Michaëlsson M. Anatomy of congenital complete heart block and relation to maternal anti-Ro antibodies. Am J Cardiol 1986; 58:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Askanase AD, Friedman DM, Copel J, et al. Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies. Lupus 2002; 11:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chockalingam P, Jaeggi ET, Rammeloo LA, et al. Persistent fetal sinus bradycardia associated with maternal anti-SSA/Ro and anti-SSB/La antibodies. J Rheumatol 2011; 38:2682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Llanos C, Friedman DM, Saxena A, et al. Anatomical and pathological findings in hearts from fetuses and infants with cardiac manifestations of neonatal lupus. Rheumatology (Oxford) 2012; 51:1086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cuneo BF, Strasburger JF, Niksch A, et al. An expanded phenotype of maternal SSA/SSB antibody-associated fetal cardiac disease. J Matern Fetal Neonatal Med 2009; 22:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moak JP, Barron KS, Hougen TJ, et al. Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol 2001; 37:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buyon JP, Hiebert R, Copel J, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998; 31:1658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falcini F, De Simone L, Donzelli G, Cerinic MM. Congenital conduction defects in children born to asymptomatic mothers with anti-SSA/SSB antibodies: report of two cases. Ann Ital Med Int 1998; 13:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Houssiau FA, Lebacq EG. Neonatal lupus erythematosus with congenital heart block associated with maternal systemic lupus erythematosus. Clin Rheumatol 1986; 5:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hornberger LK, Al Rajaa N. Spectrum of cardiac involvement in neonatal lupus. Scand J Immunol 2010; 72:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nield LE, Silverman ED, Taylor GP, et al. Maternal anti-Ro and anti-La antibody-associated endocardial fibroelastosis. Circulation 2002; 105:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nield LE, Silverman ED, Smallhorn JF, et al. Endocardial fibroelastosis associated with maternal anti-Ro and anti-La antibodies in the absence of atrioventricular block. J Am Coll Cardiol 2002; 40:796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guettrot-Imbert G, Cohen L, Fermont L, et al. A new presentation of neonatal lupus: 5 cases of isolated mild endocardial fibroelastosis associated with maternal Anti-SSA/Ro and Anti-SSB/La antibodies. J Rheumatol 2011; 38:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrazzini G, Fasnacht M, Arbenz U, et al. Neonatal lupus erythematosus with congenital heart block and severe heart failure due to myocarditis and endocardititis of the mitral valve. Intensive Care Med 1996; 22:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saxena A, Izmirly PM, Bomar RP, et al. Factors associated with long-term cardiac dysfunction in neonatal lupus. Ann Rheum Dis 2020; 79:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davey DL, Bratton SL, Bradley DJ, Yetman AT. Relation of maternal anti-Ro/La antibodies to aortic dilation in patients with congenital complete heart block. Am J Cardiol 2011; 108:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Radbill AE, Brown DW, Lacro RV, et al. Ascending aortic dilation in patients with congenital complete heart block. Heart Rhythm 2008; 5:1704.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maltret A, Morel N, Levy M, et al. Pulmonary hypertension associated with congenital heart block and neonatal lupus syndrome: A series of four cases. Lupus 2021; 30:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eliasson H, Sonesson SE, Sharland G, et al. Isolated atrioventricular block in the fetus: a retrospective, multinational, multicenter study of 175 patients. Circulation 2011; 124:1919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim KR, Yoon TY. A case of neonatal lupus erythematosus showing transient anemia and hepatitis. Ann Dermatol 2009; 21:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lynn Cheng C, Galbraith S, Holland K. Congenital lupus erythematosus presenting at birth with widespread erosions, pancytopenia, and subsequent hepatobiliary disease. Pediatr Dermatol 2010; 27:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee LA, Sokol RJ, Buyon JP. Hepatobiliary disease in neonatal lupus: prevalence and clinical characteristics in cases enrolled in a national registry. Pediatrics 2002; 109:E11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wei Sun, Yuan TM, Chen LH, Yu HM. Neonatal lupus erythematosus: three case reports and review of the Chinese literature. Clin Pediatr (Phila) 2010; 49:627.
          </a>
         </li>
         <li class="breakAll">
          Buyon JB, New York University School of Medicine, 2019, personal communication.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolach B, Choc L, Pomeranz A, et al. Aplastic anemia in neonatal lupus erythematosus. Am J Dis Child 1993; 147:941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanagasegar S, Cimaz R, Kurien BT, et al. Neonatal lupus manifests as isolated neutropenia and mildly abnormal liver functions. J Rheumatol 2002; 29:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zuppa AA, Riccardi R, Frezza S, et al. Neonatal lupus: Follow-up in infants with anti-SSA/Ro antibodies and review of the literature. Autoimmun Rev 2017; 16:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motta M, Rodriguez-Perez C, Tincani A, et al. Outcome of infants from mothers with anti-SSA/Ro antibodies. J Perinatol 2007; 27:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barsalou J, Jaeggi E, Laskin CA, et al. Prenatal exposure to antimalarials decreases the risk of cardiac but not non-cardiac neonatal lupus: a single-centre cohort study. Rheumatology (Oxford) 2017; 56:1552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boros CA, Spence D, Blaser S, Silverman ED. Hydrocephalus and macrocephaly: new manifestations of neonatal lupus erythematosus. Arthritis Rheum 2007; 57:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Askanase AD, Izmirly PM, Katholi M, et al. Frequency of neuro-psychiatric dysfunction in anti-SSA/SSB exposed children with and without neonatal lupus. Lupus 2010; 19:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen CC, Lin KL, Chen CL, et al. Central nervous system manifestations of neonatal lupus: a systematic review. Lupus 2013; 22:1484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malek A, Sager R, Kuhn P, et al. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol 1996; 36:248.
          </a>
         </li>
         <li class="breakAll">
          Buyon J, New York University School of Medicine, 2023, personal communication.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donofrio MT, Moon-Grady AJ, Hornberger LK, et al. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. Circulation 2014; 129:2183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sonesson SE, Ambrosi A, Wahren-Herlenius M. Benefits of fetal echocardiographic surveillance in pregnancies at risk of congenital heart block: single-center study of 212 anti-Ro52-positive pregnancies. Ultrasound Obstet Gynecol 2019; 54:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cuneo BF, Buyon JP. Keeping upbeat to prevent the heartbreak of anti-Ro/SSA pregnancy. Ultrasound Obstet Gynecol 2019; 54:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ciardulli A, D'Antonio F, Magro-Malosso ER, et al. Maternal steroid therapy for fetuses with second-degree immune-mediated congenital atrioventricular block: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 2018; 97:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman DM, Kim MY, Copel JA, et al. Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. Am J Cardiol 2009; 103:1102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doti PI, Escoda O, Cesar-Díaz S, et al. Congenital heart block related to maternal autoantibodies: descriptive analysis of a series of 18 cases from a single center. Clin Rheumatol 2016; 35:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levesque K, Morel N, Maltret A, et al. Description of 214 cases of autoimmune congenital heart block: Results of the French neonatal lupus syndrome. Autoimmun Rev 2015; 14:1154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van den Berg NW, Slieker MG, van Beynum IM, et al. Fluorinated steroids do not improve outcome of isolated atrioventricular block. Int J Cardiol 2016; 225:167.
          </a>
         </li>
         <li class="breakAll">
          Buyon JP, New York University School of Medicine, 2017, personal communication.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glickstein JS, Buyon J, Friedman D. Pulsed Doppler echocardiographic assessment of the fetal PR interval. Am J Cardiol 2000; 86:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phoon CK, Kim MY, Buyon JP, Friedman DM. Finding the "PR-fect" solution: what is the best tool to measure fetal cardiac PR intervals for the detection and possible treatment of early conduction disease? Congenit Heart Dis 2012; 7:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaeggi ET, Silverman ED, Laskin C, et al. Prolongation of the atrioventricular conduction in fetuses exposed to maternal anti-Ro/SSA and anti-La/SSB antibodies did not predict progressive heart block. A prospective observational study on the effects of maternal antibodies on 165 fetuses. J Am Coll Cardiol 2011; 57:1487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Medicine SFM, Planning SOF, Norton ME, et al. Society for Maternal-Fetal Medicine Consult Series #59: The use of analgesia and anesthesia for maternal-fetal procedures. Contraception 2022; 106:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cuneo BF, Buyon JP, Sammaritano L, et al. Knowledge is power: regarding SMFM Consult Series #64: Systemic lupus erythematosus in pregnancy. Am J Obstet Gynecol 2023; 229:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol 2020; 72:529.
          </a>
         </li>
         <li class="breakAll">
          Silverman ED. Neonatal lupus. In: Textbook of pediatric rheumatology, Cassidy JT, Petty RE (Eds), WB Saunders, Philadelphia 2001. p.456.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams C, Merchant WJ, Clark SM. Familial annular erythema--a rare dermatology diagnosis. Pediatr Dermatol 2011; 28:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saha A, Seth J, Mukherjee S, Basu S. Annular erythema of infancy: A diagnostic challenge. Indian J Pediatr Dermatol 2014; 15:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           del Boz J, Serrano Mdel M, Gómez E, Vera A. Neonatal lupus erythematosus and cutis marmorata telangiectatica congenita-like lesions. Int J Dermatol 2009; 48:1206.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6402 Version 33.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21969015" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26835701" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Assessment of fluorinated steroids to avert progression and mortality in anti-SSA/Ro-associated cardiac injury limited to the fetal conduction system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20012231" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11508435" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12838197" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15476223" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18195175" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25800217" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The clinical spectrum of autoimmune congenital heart block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19252519" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11755298" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. A single institution's experience of 30 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3494943" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The neonatal lupus syndrome associated with U1RNP (nRNP) antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18625627" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3891174" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Antinuclear, anticytoplasmic, and anti-Sjogren's syndrome antigen A (SS-A/Ro) antibodies in female blood donors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22237992" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Prevalence and sociodemographic correlates of antinuclear antibodies in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22237992" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Prevalence and sociodemographic correlates of antinuclear antibodies in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9733476" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The increasing incidence of isolated congenital heart block in Finland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19790064" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11508420" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Anti-Ro/SSA antibodies and congenital heart block: necessary but not sufficient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4273004" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Congenital complete heart block: an international study of the natural history.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20131261" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22626746" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35501147" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Health Outcomes of 215 Mothers of Children With Autoimmune Congenital Heart Block: Analysis of the French Neonatal Lupus Syndrome Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36996277" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Maternal Anti-Ro Antibody Titers Obtained With Commercially Available Immunoassays Are Strongly Associated With Immune-Mediated Fetal Heart Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16906225" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11046070" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Anti-SSA/Ro and anti-SSB/La autoantibodies bind the surface of apoptotic fetal cardiocytes and promote secretion of TNF-alpha by macrophages.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Histologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathogenesis of congenital heart block (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12165545" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Transdifferentiation of cardiac fibroblasts, a fetal factor in anti-SSA/Ro-SSB/La antibody-mediated congenital heart block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8113406" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Cellular mechanism of the conduction abnormalities induced by serum from anti-Ro/SSA-positive patients in rabbit hearts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11257091" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Direct inhibition of expressed cardiac l- and t-type calcium channels by igg from mothers whose children have congenital heart block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21352396" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Rescue and worsening of congenital heart block-associated electrocardiographic abnormalities in two transgenic mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24039792" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Congenital heart block maternal sera autoantibodies target an extracellular epitope on theα1G T-type calcium channel in human fetal hearts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25994441" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Reactivity to the p305 Epitope of theα1G T-Type Calcium Channel and Autoimmune-Associated Congenital Heart Block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31589297" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Cell atlas of the foetal human heart and implications for autoimmune-mediated congenital heart block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30518570" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Siglec-1 Macrophages and the Contribution of IFN to the Development of Autoimmune Congenital Heart Block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33004330" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Natural killer cells and type II interferon in Ro/SSA and La/SSB autoantibody-exposed newborns at risk of congenital heart block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37090702" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Contribution of S100A4-expressing fibroblasts to anti-SSA/Ro-associated atrioventricular nodal calcification and soluble S100A4 as a biomarker of clinical severity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8216420" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. Comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti-SS-A/Ro and anti-SS-B/La antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3262756" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Complete congenital heart block: risk of occurrence and therapeutic approach to prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15570655" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20538173" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus a prospective study of 186 antibody-exposed fetuses and infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28177533" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Serial echocardiography for immune-mediated heart disease in the fetus: results of a risk-based prospective surveillance strategy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35690080" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Reducing the burden of surveillance in pregnant women with no history of fetal atrioventricular block using the negative predictive value of anti-Ro/SSA antibody titers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16802359" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Anti-La/SSB antiidiotypic antibodies in maternal serum: a marker of low risk for neonatal lupus in an offspring.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18383373" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : A B cell apotope of Ro 60 in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16356190" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : 52-kDa Ro/SSA epitopes preferentially recognized by antibodies from mothers of children with neonatal lupus and congenital heart block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15630133" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18727629" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Antibodies to amino acid 200-239 (p200) of Ro52 as serological markers for the risk of developing congenital heart block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16200587" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Maternal antibody responses to the 52-kd SSA/RO p200 peptide and the development of fetal conduction defects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22511615" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Umbilical cord blood levels of maternal antibodies reactive with p200 and full-length Ro 52 in the assessment of risk for cardiac manifestations of neonatal lupus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7748740" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : U1RNP positive neonatal lupus erythematosus: association with anti-La antibodies?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20582918" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Doppler fetal mechanical PR interval prolongation with positive maternal anti-RNP but negative SSA/Ro and SSB/La auto-antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28709760" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Clinical and pathologic implications of extending the spectrum of maternal autoantibodies reactive with ribonucleoproteins associated with cutaneous and now cardiac neonatal lupus from SSA/Ro and SSB/La to U1RNP.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10025600" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Role of HLA in congenital heart block: susceptibility alleles in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20662065" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Identification of candidate loci at 6p21 and 21q22 in a genome-wide association study of cardiac manifestations of neonatal lupus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24354957" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : The HLA locus contains novel foetal susceptibility alleles for congenital heart block with significant paternal influence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15334474" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Genetic association of cutaneous neonatal lupus with HLA class II and tumor necrosis factor alpha: implications for pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14630442" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Myocardial-tissue-specific phenotype of maternal microchimerism in neonatal lupus congenital heart block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28535210" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Facial Rash, Fever, and Anemia in a Newborn.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25639144" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Seeing double: annular diaper rash in twins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16008650" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Neonatal lupus erythematosus presenting as papules on the feet.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20696019" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Non-cardiac manifestations of neonatal lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11060534" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Cutaneous manifestations of neonatal lupus without heart block: characteristics of mothers and children enrolled in a national registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11564370" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Neonatal lupus: clinical features, therapy, and pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22170760" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Facial telangiectasia: an unusual manifestation of neonatal lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12355485" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Long-term followup of children with neonatal lupus and their unaffected siblings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Development of autoimmune diseases and genetic predisposition in children with neonatal lupus and their unaffected siblings [abstract]
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19515045" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Histopathologic characteristics of neonatal cutaneous lupus erythematosus: description of five cases and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30297329" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30309472" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Home Monitoring for Fetal Heart Rhythm During Anti-Ro Pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3090867" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Anatomy of congenital complete heart block and relation to maternal anti-Ro antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11999879" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22089457" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Persistent fetal sinus bradycardia associated with maternal anti-SSA/Ro and anti-SSB/La antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22308531" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Anatomical and pathological findings in hearts from fetuses and infants with cardiac manifestations of neonatal lupus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19330707" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : An expanded phenotype of maternal SSA/SSB antibody-associated fetal cardiac disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11153745" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9626848" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9859574" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Congenital conduction defects in children born to asymptomatic mothers with anti-SSA/SSB antibodies: report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3816098" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Neonatal lupus erythematosus with congenital heart block associated with maternal systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20696015" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Spectrum of cardiac involvement in neonatal lupus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11854125" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Maternal anti-Ro and anti-La antibody-associated endocardial fibroelastosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12204513" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Endocardial fibroelastosis associated with maternal anti-Ro and anti-La antibodies in the absence of atrioventricular block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21078712" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : A new presentation of neonatal lupus: 5 cases of isolated mild endocardial fibroelastosis associated with maternal Anti-SSA/Ro and Anti-SSB/La antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8796403" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Neonatal lupus erythematosus with congenital heart block and severe heart failure due to myocarditis and endocardititis of the mitral valve.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31672776" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Factors associated with long-term cardiac dysfunction in neonatal lupus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21624539" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Relation of maternal anti-Ro/La antibodies to aortic dilation in patients with congenital complete heart block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18990611" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Ascending aortic dilation in patients with congenital complete heart block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33198562" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Pulmonary hypertension associated with congenital heart block and neonatal lupus syndrome: A series of four cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21986286" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Isolated atrioventricular block in the fetus: a retrospective, multinational, multicenter study of 175 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20523814" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : A case of neonatal lupus erythematosus showing transient anemia and hepatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20199433" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Congenital lupus erythematosus presenting at birth with widespread erosions, pancytopenia, and subsequent hepatobiliary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11773579" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Hepatobiliary disease in neonatal lupus: prevalence and clinical characteristics in cases enrolled in a national registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20118099" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Neonatal lupus erythematosus: three case reports and review of the Chinese literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20118099" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Neonatal lupus erythematosus: three case reports and review of the Chinese literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8362807" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Aplastic anemia in neonatal lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11824959" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Neonatal lupus manifests as isolated neutropenia and mildly abnormal liver functions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28212920" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Neonatal lupus: Follow-up in infants with anti-SSA/Ro antibodies and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17363909" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Outcome of infants from mothers with anti-SSA/Ro antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28595349" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Prenatal exposure to antimalarials decreases the risk of cardiac but not non-cardiac neonatal lupus: a single-centre cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17330304" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Hydrocephalus and macrocephaly: new manifestations of neonatal lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20008445" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Frequency of neuro-psychiatric dysfunction in anti-SSA/SSB exposed children with and without neonatal lupus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24142583" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Central nervous system manifestations of neonatal lupus: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8955500" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Evolution of maternofetal transport of immunoglobulins during human pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8955500" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Evolution of maternofetal transport of immunoglobulins during human pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24763516" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30620419" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Benefits of fetal echocardiographic surveillance in pregnancies at risk of congenital heart block: single-center study of 212 anti-Ro52-positive pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31313868" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Keeping upbeat to prevent the heartbreak of anti-Ro/SSA pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29512819" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Maternal steroid therapy for fetuses with second-degree immune-mediated congenital atrioventricular block: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19361597" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26791874" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Congenital heart block related to maternal autoantibodies: descriptive analysis of a series of 18 cases from a single center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26284740" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Description of 214 cases of autoimmune congenital heart block: Results of the French neonatal lupus syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27728859" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Fluorinated steroids do not improve outcome of isolated atrioventricular block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27728859" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Fluorinated steroids do not improve outcome of isolated atrioventricular block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10913494" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Pulsed Doppler echocardiographic assessment of the fetal PR interval.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22494551" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Finding the "PR-fect" solution: what is the best tool to measure fetal cardiac PR intervals for the detection and possible treatment of early conduction disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21435519" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Prolongation of the atrioventricular conduction in fetuses exposed to maternal anti-Ro/SSA and anti-La/SSB antibodies did not predict progressive heart block. A prospective observational study on the effects of maternal antibodies on 165 fetuses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34740602" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Society for Maternal-Fetal Medicine Consult Series #59: The use of analgesia and anesthesia for maternal-fetal procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37394327" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Knowledge is power: regarding SMFM Consult Series #64: Systemic lupus erythematosus in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32090480" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32090480" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21276056" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Familial annular erythema--a rare dermatology diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Annular erythema of infancy: A diagnostic challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20064177" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Neonatal lupus erythematosus and cutis marmorata telangiectatica congenita-like lesions.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
